HC Wainwright & Co. Assumes HIVE Blockchain Techs at Buy, Announces Price Target of $5
HC Wainwright & Co. analyst Mike Colonnese assumes HIVE Blockchain Techs (NASDAQ:HIVE) with a Buy rating and announces Price Target of $5.
Jefferies Initiates Coverage On Compass Therapeutics with Buy Rating, Announces Price Target of $8
Jefferies analyst Maury Raycroft initiates coverage on Compass Therapeutics (NASDAQ:CMPX) with a Buy rating and announces Price Target of $8.
Zacks Investment Research Initiates Coverage On Expion360, Announces Price Target of $4.25
Zacks Investment Research analyst Brian Lantier initiates coverage on Expion360 (NASDAQ:XPON) and announces Price Target of $4.25.
Piper Sandler Initiates Coverage On Incyte with Overweight Rating, Announces Price Target of $100
Piper Sandler analyst Allison Bratzel initiates coverage on Incyte (NASDAQ:INCY) with a Overweight rating and announces Price Target of $100.
EF Hutton Initiates Coverage On Onfolio Holdings with Buy Rating, Announces Price Target of $3
EF Hutton analyst Michael Albanese initiates coverage on Onfolio Holdings (NASDAQ:ONFO) with a Buy rating and announces Price Target of $3.
EF Hutton Initiates Coverage On Xencor with Buy Rating, Announces Price Target of $42
EF Hutton analyst Michael King initiates coverage on Xencor (NASDAQ:XNCR) with a Buy rating and announces Price Target of $42.
BioMarin Valuation Fair, But Expectations From Hemophilia Therapy Too High, Says Analyst
BMO Capital Markets initiated coverage on BioMarin Pharmaceutical Inc (NASDAQ:BMRN) with a Market Perform rating and a price target of $107. Related: BioMarin’s…
BMO Capital Markets Says 4D Molecular Could Be ‘Attractive Acquisition Target’
BMO Capital Markets initiated coverage on 4D Molecular Therapeutics Inc (NASDAQ:FDMT) with an Outperform rating and a price target of $50. The…
Lake Street Initiates Coverage On Tremor Intl with Buy Rating, Announces Price Target of $12
Lake Street analyst Eric Martinuzzi initiates coverage on Tremor Intl (NASDAQ:TRMR) with a Buy rating and announces Price Target of $12.
Goldman Sachs Initiates Coverage On Macy’s with Buy Rating, Announces Price Target of $28
Goldman Sachs analyst Brooke Roach initiates coverage on Macy's (NYSE:M) with a Buy rating and announces Price Target of $28.